EAM
SLNO

Empery Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Empery Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-93,427
Closed -$313K – 81
2022
Q1 		$313K Buy
+93,427
New +$484K 1.47% 16

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Empery Asset Management's SLNO Position: Q2 2022 in Review

Empery Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2022, closing a stake of 93,427 shares — an estimated $313K sold.

Empery Asset Management first reported a position in SLNO in Q1 2022 and held it in 1 quarter. The position peaked at $313K in Q1 2022. 40 funds tracked by Wall St. Rank hold SLNO as of Q2 2022.

  • Empery Asset Management reported no remaining Soleno Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Empery Asset Management sold 93,427 Soleno Therapeutics shares in Q2 2022, an estimated $313K.
  • Empery Asset Management first reported a position in Soleno Therapeutics in Q1 2022 and held it in 1 quarter.
  • Empery Asset Management's Soleno Therapeutics position peaked at $313K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2022.

Based on Empery Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.